Edition:
United States

Collplant Holdings Ltd (CLGN.OQ)

CLGN.OQ on NASDAQ Stock Exchange Capital Market

5.40USD
16 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.40
Open
$5.39
Day's High
$5.39
Day's Low
$5.39
Volume
25
Avg. Vol
2,139
52-wk High
$10.19
52-wk Low
$4.99

Latest Key Developments (Source: Significant Developments)

Collplant Reports Q1 Non-GAAP Loss Per Share $0.01
Thursday, 24 May 2018 05:50am EDT 

May 24 (Reuters) - Collplant Holdings Ltd ::COLLPLANT REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 REVENUE ILS 779,000.Q1 NON-GAAP LOSS PER SHARE $0.01.  Full Article

CollPlant Q4 Revenue Rose 375 Percent To ILS 952,000
Wednesday, 21 Mar 2018 06:45am EDT 

March 21 (Reuters) - Collplant Holdings Ltd ::COLLPLANT REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 REVENUE ROSE 375 PERCENT TO ILS 952,000.Q4 LOSS PER SHARE $0.01.  Full Article

CollPlant receives innovation authority approval for R&D Program
Monday, 30 Oct 2017 10:04am EDT 

Oct 30 (Reuters) - Collplant Holdings Ltd :Says received Ministry Of Economy Innovation Authority's approval for Collplant's research and development program for 2017​.  Full Article

Collplant Holdings Ltd signs a new, exclusive distributor agreement in Turkey
Monday, 22 May 2017 09:15am EDT 

May 22 (Reuters) - Collplant Holdings Ltd : :Collplant Holdings Ltd - signed a new, exclusive distributor agreement in Turkey to market Vergenix FG, for treatment of chronic wounds.Collplant Holdings Ltd - market potential for treatment of chronic wounds in Turkey is estimated at in excess of 400,000 procedures annually.  Full Article

Collplant Holdings reports positive results from post-marketing surveillance of Vergenix FG
Tuesday, 11 Apr 2017 11:47am EDT 

Collplant Holdings Ltd : Announce positive results from post-marketing surveillance of company's advanced wound care product, Vergenix FG . As part of surveillance, co monitored 10 patients following a single treatment with Vergenix FG in hospitals in Italy, Switzerland .Study showed 5 weeks post treatment, patients displayed average wound closure rate of 80%, with no observed safety/ tolerability issues.  Full Article

Collplant provides commercial and operational update
Thursday, 30 Mar 2017 06:00am EDT 

Collplant Holdings Ltd : Collplant provides commercial and operational update .Pursuing joint ventures with international companies to further advance Bioink in specific indications in 2017.  Full Article

CollPlant sees U.S. IPO of 3.5 mln ADSs
Friday, 25 Nov 2016 06:27am EST 

CollPlant Holdings Ltd :CollPlant Holdings Ltd sees U.S. IPO of 3.5 million American Depositary Shares - SEC filing.  Full Article

Collplant signs exclusive distribution agreement with Arthrex for Vergenix STR
Tuesday, 8 Nov 2016 09:21am EST 

Collplant Holdings Ltd : Collplant signs exclusive distribution agreement with Arthrex for Vergenix STR . Collplant Holdings says from Dec 1, Arthrex to be exclusive distributor of CE marked Vergenix STR in Europe, Middle-East, India, some African countries .Collplant Holdings says agreement includes common commercial terms and first order is expected to be supplied next month.  Full Article